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Abstract
In acute myeloid leukemia (AML) quiescence and low oxidative state, linked to BCL2 mito-
chondrial regulation, endow leukemic stem cells (LSC) with treatment-resistance. LSC in
CD34+ and more mature CD34− AML have heterogeneous immunophenotypes overlap-
ping with normal stem/progenitor cells (SPC) but may be differentiated by functional mark-
ers. We therefore investigated the oxidative/reactive oxygen species (ROS) profile, its
relationship with cell-cycle/BCL2 for normal SPC, and whether altered in AML and myelo-
dysplasia (MDS). In control BM (n = 24), ROS levels were highest in granulocyte-macro-
phage progenitors (GMP) and CD34− myeloid precursors but megakaryocyte-erythroid
progenitors had equivalent levels to CD34+CD38low immature-SPC although they were
ki67high. BCL2 upregulation was specific to GMPs. This profile was also observed for
CD34+SPC in MDS-without-excess-blasts (MDS-noEB, n = 12). Erythroid CD34− precur-
sors were, however, abnormally ROS-high in MDS-noEB, potentially linking oxidative
stress to cell loss. In pre-treatment AML (n = 93) and MDS-with-excess-blasts (MDS-
RAEB) (n = 14), immunophenotypic mature-SPC had similar ROS levels to co-existing
immature-SPC. However ROS levels varied between AMLs; Flt3ITD+/NPM1wild-type
CD34+SPC had higher ROS than NPM1mutated CD34+ or CD34− SPC. An aberrant
ki67lowBCL2high immunophenotype was observed in CD34+AML (most prominent in
Flt3ITD AMLs) but also in CD34− AMLs and MDS-RAEB, suggesting a shared redox/pro-
survival adaptation. Some patients had BCL2 overexpression in CD34+ ROS-high as well
as ROS-low fractions which may be indicative of poor early response to standard chemo-
therapy. Thus normal SPC subsets have distinct ROS, cell-cycle, BCL2 profiles that in
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AML /MDS-RAEB are decoupled from maturation. The combined profile of these functional
properties in AML subpopulations may be relevant to differential treatment resistance.
Introduction
Recent years have witnessed accelerated interest in the role of reactive oxygen species (ROS) in
both normal hematopoietic development and leukemogenesis and in how redox modulation
may impact on therapeutic strategies for acute myeloid leukemia (AML) [1,2].
ROS serve as mediators in proliferation and differentiation of hematopoietic cells, either via
a paracrinemechanism [3], or by intracellular ROS production induced by cytokine receptor
engagement on hematopoietic cells [4–7]. Normal hematopoietic stem cells (HSC) however
require fine-tuning of low intracellular ROS levels in order to maintain quiescence, limit oxida-
tive stress damage and sustain lifelong haematopoiesis. The metabolic adjustment of HSCs to
reliance on glycolysis with resulting low ROS levels is due to the local conditions of hypoxic
bonemarrow (BM) niches, and also transcription/signallingpathways that alter ROS homeo-
stasis and are critical for HSC function [8]. Gene targeting of regulatorymolecules such as
FoxO and Atm leads to higher ROS in HSC and loss of quiescence and self-renewal [9,10].
Conversely, manipulations that decrease ROS levels cause increasedHSC quiescence and loss
of effective differentiation into downstream progenitors [11]. Inefficient ROS homeostasis
resulting in oxidative stress and genetic instability in HSCs and myeloid progenitors has been
linked to myeloid malignancy; [12–14] for example high ROS levels have been correlated with
greater DNA damage in AML with Flt3-internal-tandem-duplication (ITD) [15] and may
explain the poor prognosis [16]. Furthermore overproduction of ROS in AML drives growth
factor independent proliferation of AML blasts [17,18].
Flow cytometric analyses with fluorescent ROS-indicator dyes show that quiescent drug-
resistant cancer and AML leukemic stem cells (LSC) are enriched in the ROS-low fraction of
total tumour cells [2,19] similarly to normal slow-cycling HSC being enriched in the ROS-low
population [20]. Unlike HSC and most cancer cells [21], AML LSC have increased depen-
dence on oxidative phosphorylation despite maintaining protective low ROS levels [2]. This
mitochondrial respiration appears to require BCL2, the overexpression of which has previ-
ously been established to have other roles in functional chemo-resistance through anti-apo-
ptosis [22] and potentially by inducing quiescence [23]. These and other mechanisms for
BCL2 dependence suggest that chemo-resistant AML LSCmay be targeted by the novel BCL2
inhibitor ABT199 /venetoclax [24,25]. However identifying and tracking chemo-resistant
LSCs in patients to evaluate the effectiveness of such new therapies or indeed standard treat-
ments is problematic since xenotransplantation assays are not applicable to routine clinical
practice and LSC immunophenotypic profiles are heterogeneous. LSC have been identified
within the lineage-negative CD34+CD38-/low compartment that contains HSC in normal hae-
matopoiesis [26,27] but also in ‘more mature’ CD34+CD38+ [28] and CD34− progenitor/pre-
cursor compartments [29,30]. Potentially, low intracellular ROS levels could be used as a
differential functionalmarker of chemo-resistant leukemic stem/progenitor cells (SPC) within
immunophenotypic subsets pre- and post-treatment, particularly if combined with quiescence
and BCL2 expression. It remains unclear, however, how ROS levels are modulated in the vari-
ous normal human progenitors downstream from normal HSC compared to their immuno-
phenotypic leukemic counterparts in AML [28] or at the intermediate/pre-leukemic stage of
MDS. In addition the relationship between ROS, BCL2 and cell-cycle status for the different
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normal and leukemic SPC subsets requires further clarification in order to understand the
relationship between emergence of SPCs with potential chemo-resistant functional properties
and maturation stage in both CD34+ and more mature CD34− AML subtypes.We sought to
investigate this, developing a novel combined flow cytometry assay to measure ROS, cell-cycle
(ki67) and the anti-apoptotic marker BCL2 in blast populations from normal, MDS and AML
patients.
Methods
Patient samples
All experiments with human clinical material were performed after receiving approval from
the University of BirminghamResearch Governance office and the NorthWest—Greater Man-
chester East Research Ethics Committee (12/NW/0742) and were conducted according to the
principles expressed in the Declaration of Helsinki. Human BM and peripheral blood (PB)
specimens were residual material from clinical samples for which institutional/ethical approv-
als were obtained. Control samples were adult (ages 43-84yrs, median 64yrs) lymphoma
patient staging BM (n = 24) with no evidence of haematological malignant cells (confirmed by
morphology and flow cytometry), and umbilical cord blood (UCB) samples (n = 4). Pre-treat-
ment BM/PB samples from AML patients (n = 93, details in S1 File and S1 Table) and BM sam-
ples frommyelodysplastic syndrome (MDS)/myeloproliferative disease (MPD) patients were
also studied (n = 26, age 32-89yrs, median 76yrs). All samples were between 24–36 hours old.
Cell staining and flow cytometry
For ROS analysis, cells were labelled with 2‘-7‘-dichlorofluoresceindiacetate (Life Technolo-
gies), hereafter abbreviated to DCF, and then with monoclonal antibodies (mAb) against SPC
markers (details in supporting information S1 File [supplementary methods], S1 Fig, and pan-
els in S2 Table). DCFmedian fluorescent intensity (MFI) values of control and diseased SPCs
were standardised by dividing these values with the DCF-MFI value of lymphocytes present
within each sample. CD45intCD117+ gating was performed to identify blasts. CD34+CD38low
cells were sub-divided into HSC (CD90+CD45RA−), multipotent progenitors (MPP;
CD45RA−CD90−) and lymphoid-primedmultipotent progenitors (LMPP; CD45RA+CD90−).
CD34+CD38high cells were sub-divided into CMP (CD45RA−CD123+), GMP (CD45RA+-
CD123+) and MEP (CD45RA−CD123−). For intracellular staining experiments chloro-methyl-
DCFwas used followed by surface and intracellular staining (ki67/BCL2 and isotype controls).
For viability assays, cells were stained with Annexin-V and 7-aminoactinomycin D (7AAD).
Data acquisition was performed on a BD-FACS-Canto-II flow cytometer and later analysed
with FlowJo (v7.6) software.
Colony forming unit (CFU) assays
To determine lineage potential FACS-sorted immunophenotypic subsets were seeded into
methylcellulosemedia (Methocult, StemCell Technologies) at 100–1000 cells per dish. CFU-
dishes were incubated at 37°C, 5%CO2 for 14-days and then scored for colonies using an
inverted light microscope. Specific colony types (CFU-GEMM,CFU-GM, CFU-M, CFU-G
and CFU-E) were expressed as percentage of total colony yield under each experimental
condition.
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Drug sensitivity assays
Freshly isolated (by Ficoll-based density gradient centrifugation) pre-treatment AML patient
cells were incubated at 37°C 5%CO2 with or without ABT199 (CaltagMedsystems) for 16
hours at a range of concentrations in duplicate. Sensitivity to ara-C (Sigma-Aldrich)was mea-
sured after incubation with drug for 48 hours. After washing, cells were stained for surface
markers and then with Annexin-V and 7AAD. Live/dead cells were then visualized by flow
cytometrywith toxicity calculated using the formula: %specific apoptosis = (test-control)×100
/ (100-control)
Results
ROS levels in control stem/progenitor cells (SPC)
We first asked whether low ROS levels measured with the redox-sensitive probe DCFwere
restricted to, and could thus differentiate HSC from, other immunophenotypic normal human
hematopoietic progenitor populations (S1 Fig). In control BM samples (n = 24) total CD34+-
CD38high cells (fraction containing committed progenitors) had higher DCF staining than total
CD34+CD38low cells (fraction containing more immature SPC) as expected. Further analysis
within these two immunophenotypic compartments (representative examples in Fig 1A) con-
firmed that HSC had low DCF staining (median standardised-DCF-MFI= 2.05), as did the
MPP population (median 1.98). The infrequent LMPP subset (<5% of CD34+CD38low) had
relatively higher DCF staining (median 2.48), compared to both HSC and MPP. Interestingly
there was a differential ROS profile within the CD34+CD38high fraction: GMP had highest
DCF staining (median 6.64), followed by CMP (median 3.41) and thenMEP (median 2.88)
(complete summarised data in Fig 2A and 2B). The hierarchy in DCF staining with
GMP>CMP>MEP and LMPP>HSC/MPPwas also observed in umbilical cord blood (UCB)
samples (n = 4) (example in Fig 1B), suggesting that this ROS profile is representative of nor-
mal non-malignant human SPC and not specific to the BMmicroenvironment.
Lineage fate and viability of CD34+CD38high cells with different ROS
levels
The relationship betweenROS levels and immunophenotypic normal progenitors (CD34+-
CD38high fraction) was further assessed by colony assays using purified progenitor subsets
from control BM (n = 3). CD34+CD38highCD45RA+ cells (GMP-enriched) and CD34+-
CD38highCD45RA−cells (CMP/MEP-enriched), were sorted into four populations denoted
DCFlow, DCFint1, DCFint2 and DCFhigh (Fig 3A) and assayed for colony output after 14 days
culture in vitro. Results from CD45RA−cells showed that mixed (CFU-GEMM) and erythroid
(CFU-E) potential was limited to DCFlow/DCFint1 fractions and was lost in DCFint2/DCFhigh
fractions. Only granulocyte/macrophage colonies were generated in DCFint2 and DCFhigh frac-
tions (Fig 3B). CD45RA+ cells exclusively generated granulocyte (CFU-G) and macrophage
(CFU-M) or mixed GM colonies (CFU-GM)with a relative reduction in CFU-GM and
increase in CFU-M observedwith increasing DCF (DCFint2/DCFhigh fraction) (Fig 3C). Thus,
higher ROS in the CD45RA−(CMP/MEP-enriched) compartment correlates with reducedmul-
tipotency, loss of erythroid potential and commitment towards GMP while higher ROS in the
CD45RA+ (GMP-enriched) compartment correlates with loss of mixed GM potential and
higher macrophage potential.
High intracellular ROS levels may predispose GMP to greater risk of apoptosis. In CFU
assays, total colony yields were progressively lower with increasing ROS levels (Fig 3D), sug-
gesting that higher ROS impedes cell proliferation and survival during cell culture. We
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Fig 1. ROS levels in immunophenotypic stem/progenitor cells from representative normal control, myelodysplastic
and AML bone marrows. Flow cytometry histograms show intracellular ROS levels (using DCF) in HSC/MPP/LMPP and CMP/
GMP/MEP of representative control BM (A), umbilical cord blood (UCB) (B), four AML BM samples at diagnosis (C), two MDS-
RAEB BM samples (D), and two MDS-no-EB BM samples (E). DCF staining with normalised mean fluorescence intensity of
each of these populations is shown (using DCF staining of reference lymphocyte population shown as light grey filled histogram,
while for stem/progenitor subsets staining is shown as open histograms with different coloured lines as indicated on each plot).
Additional examples of DCF staining of AML and MDS samples are shown in S1F–S1H Fig.
doi:10.1371/journal.pone.0163291.g001
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Fig 2. Summarised ROS levels in control, dysplastic and leukemic CD34+ and CD34− blasts. Charts show normalised DCF MFI
(relative to lymphocytes within each sample) of CD34+CD38low subsets (A) and CD34+CD38high subsets (B) from control BM (n = 24), and
AML BM (n = 27), MDS/MPD-no-EB BM (n = 12) and MDS-RAEB BM (n = 14). Flt3ITD+ AML = red filled square. CBF-AMLs = green filled
squares (see Key in figure). ROS levels in CD34−CD117+ cells were also compared between control BM and CD34− AML (n = 10) and
MDS patient BM samples, using the same colour scheme as above (C). CD34−CD117+ cells were subdivided into CD45RA+ and
CD45RA−cells to enrich for myeloid and erythroid precursors respectively. Median expression and interquartile range is shown on each
plot. P values are shown for data-sets where significant differences were observed (p<0.05, Mann Whitney test with 95% confidence
intervals).
doi:10.1371/journal.pone.0163291.g002
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Fig 3. Influence of ROS levels on lineage fate and viability in normal progenitors. Sorting scheme of
normal BM CD34+CD38high cells separated into CD45RA+ and CD45RA−subsets, followed by gating into 4
different populations based on differential DCF staining (A). Sorted cells were seeded onto methylcellulose
media supplemented with cytokines. After 2 week culture at 37˚C in vitro, colonies were scored using an inverted
light microscope and recorded as a percentage of the total colony yield for FACS-sorted control CD34+CD38high
CD45RA−(B) and CD34+CD38high CD45RA+ (C) progenitors with different levels of DCF staining. Total colony
yield as percentage of input cell number was also determined (D). Colony forming unit assay data is from three
Functional Profiles of Normal and AML Stem/Progenitor Cells
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evaluated cell viability in control BM cells (n = 7) (Fig 3E). Total CD34+CD38low cells and
MEP, which are both low for ROS, had the highest viability (>96.5%) while CMP and GMP,
which are high in ROS, both had lower frequencies of viable Annexin-V−/7AAD−cells (86%
and 84% respectively).We investigated whether SPCs with higher ROS might be more sensitive
to apoptosis by further oxidative insult (such as that generated by chemotherapy) by overnight
treatment with the pro-oxidant BSO. This caused increasedDCF staining but did not alter the
number of apoptotic cells within CMP/GMP subsets (Fig 3F and 3G), suggesting that these
cells have a relative protection against rapid induction of apoptosis from higher ROS levels.
Altered ROS levels in AML and MDS CD34+ cells
We next evaluated the heterogeneity of the leukemic SPC ROS profile in AML patient samples
to determine whethermore mature immunophenotypic leukemic CMP/GMP subsets might
include aberrantly low ROS (putative LSC-enriched [2]) populations.
CD34+ AML (cases with>5% blast cells being CD34+) BM samples (n = 29) consisted of
either abnormally expanded LMPP-/GMP-like populations (>90% of CD34+ blasts, in 15/29
samples), MPP-/CMP-like populations (>90% of blasts, n = 6) (examples in S1 Fig), GMP-like
(>99% of blasts, n = 1), CMP-/GMP-like (>99% of blasts, n = 2), or a mixture of all SPC-types
(n = 5). AML samples showed variable DCF-measuredROS levels that fell within the range of
MFI values observedwith control BMs. However, in contrast to normal SPC profiles, and
despite immunophenotypic heterogeneity, co-existing CD34+CD38low and CD34+CD38high
leukemic-SPCs in AML BM samples often had similar intracellular ROS levels (examples of
LMPP/GMP-like and MPP/CMP-like AML in Fig 1C, and additional examples in S1F Fig).
DCF staining was significantly lower in GMP-like (median 3.83) leukemic subsets when com-
pared to the equivalent control SPC (Fig 2A and 2B, p<0.0001).
AML blasts also circulate in peripheral blood (PB) but it is unclear whether ROS profiles of
leukemic-SPC are modulated by dissociation from hypoxic BM niches. We compared DCF-
measured ROS levels of CD34+ subsets in unpaired PB (n = 43) and BM (n = 27) presentation
samples and in 8 paired BM/PB AML samples. Abnormally expanded SPC observed in AML
BM samples were also present in AML PB diagnosis samples. The unpaired PB vs. BM compar-
ison showed a similar range of DCF staining between sample types (S2 Fig). Paired samples
showed very similar immunophenotypes and a trend of lower DCF staining in PB in 5 out of 8
cases (S2 Fig), suggesting that the lower ROS equilibrium of some CD34+ AML SPC is main-
tained outside the hypoxic BMmicroenvironment and may be reduced further.
MDS with excess blasts (RAEB) patients had abnormally expanded CD34+CD38low cells in
13 of 14 samples tested (8/9 BM, 5/5 PB) (example in S1D Fig). Most of these samples showed
low DCF staining in all CD34+ subsets (examples in Fig 1D), as observed in AML samples,
while one sample had low DCF staining in all CD34+CD38low subsets but retained high DCF
levels in CD34+CD38high GMP (examples in S1G Fig). In contrast, MDS without excess blasts
(MDS-noEB) samples (n = 12), mostly showed higher DCF staining across CD34+ subsets, par-
ticularly in GMP fractions (examples in Fig 1E and S1H Fig, summarised data in Fig 2A and
2B). Thus, the transition of myeloid-committed CD34+CD38high SPCs to lower ROS appears to
occur later in pre-leukemic progression.
independent experiments. Colonies were scored as erythroid (e), macrophage (m), granulocyte (g), granulocyte-
macrophage (gm), or granulocyte-erythroid-macrophage mixed (gemm). Viability was determined by Annexin V
and 7-AAD staining of normal BM labelled with HSPC-specific mAb. Initial gating was performed on SSClow
CD45intCD117+ cells. The pooled viability data from 7 control BM sample are shown (E). The effects of redox
modification on DCF staining and cell viability in CD34+CD38high progenitors, is shown from two independent
experiments (F). BM cells were treated overnight with the pro-oxidant BSO (100μM) or left untreated (control).
doi:10.1371/journal.pone.0163291.g003
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ROS levels in control, AML and MDS CD34− subsets
We then investigated whether the altered ROS profile of AML CD34+SPCs is also adapted in
the immunophenotypically more mature CD34− blast compartment from CD34− AML sam-
ples (defined as cases where<5% blasts cells are CD34+) (n = 23).
First, normal BM CD34− CD117+ cells (more differentiated hematopoietic precursors)
were analysed, separated into CD45RA+ and CD45RA−cells to enrich for myeloid and ery-
throid precursors respectively, (confirmed by CD33 and CD71/CD235a staining). CD45RA+
cells were DCF-high (median DCFMFI 6.54) while CD45RA−cells had intermediate DCF
staining (MFI 4.37) (Fig 2C). In comparison only 3 of 23 CD34− AMLs had CD34− CD117+
DCF-high progenitors (>MFI 5.0), and overall the CD34− CD117+ cells were DCF-low when
compared with their normal immunophenotypic counterparts whether CD45RA+ or
CD45RA−(Fig 2C) with no difference observedbetween unpaired BM (n = 10) and PB
(n = 11) samples (S2 Fig).
Similarly to AML, CD34− CD45RA+ as well as CD34− CD45RA−cells were DCF-low in
MDS-RAEB samples. Interestingly, in MDS—noEBDCF staining of CD34−CD45RA−cells
(erythroid-enrichedprecursors) was significantly higher (p = 0.03) than normal CD34−
CD45RA−cells (Fig 2C).
ROS levels in AML genetic subgroups
ROS have previously been linked to leukemogenesis of core binding factor (CBF)-AML [31]
and genomic instability of Flt3ITD+ AML [15,32]. We therefore assessed the relative DCF-
measured ROS levels in these and NPM1 genetic subgroups (cytogenetic/molecularpatient
characteristics in S1 Table) in the dominant blast population (CD34+ in CD34+AML; n = 70
[29 BM/ 41 PB], or CD34− CD117+ in CD34− AML; n = 23 [10 BM/ 13 PB]).
In CD34+ AMLs (Fig 4A), CBF-AMLs (n = 4) had globally higher ROS levels than Flt3ITD−/
NPM1wild type (wt) patients (MFI 4.61 vs 2.28, p = 0.03). Flt3ITD+/NPM1wt cases (n = 6)
overall also displayed significantly higher ROS than Flt3ITD–/NPM1wtAMLs (n = 44) (MFI
4.48 vs 2.28, p = 0.04) in total CD34+ cells and a trend to higher than Flt3ITD–/NPM1mutated
CD34+AMLs (n = 7) (MFI 4.48 vs 2.86; p = 0.07). In 3/6 of Flt3ITD+/NPM1wt patients, all SPC
types were ROS-high, with DCFMFI of>5.0, the 75% percentile for all patients (S2 Fig).
In this cohort all Flt3ITD+/NPM1mutated patients (n = 9) were CD34− AMLs (Fig 4B).
These had overall lower ROS levels in their blasts (MFI 3.19) comparable to Flt3ITD−/
NPM1mutated CD34− AML blasts (MFI 3.34). These results suggest that a co-existing
NPM1mutation may mitigate the increased ROS levels associated with Flt3ITD+AML.
Combined analyses of BCL2 / ki67 with ROS in control and AML/MDS
SPCs
Although ROS, BCL2 expression and cell-cycle status have previously been functionally linked
[2,23,33,34] there are as yet no data assessing these therapeutically relevant parameters in par-
allel for normal or leukemic SPC subsets.We therefore developed and performed a combined
assay on control BM (n = 16), AML diagnosis samples (n = 40) and MDS samples (n = 12).
In control BMs CD34+CD38high cells expressed higher levels of both ki67 and BCL2 than
CD34+CD38low cells (example in Fig 5A). Closer inspection (in 11 cases) showed that although
there was no significant difference in ki67 betweenCMP, GMP andMEP subsets, BCL2 expres-
sion followed a GMP>CMP>MEP hierarchy (S3A and S3B Fig) as observed for ROS levels.
Within the more immature CD34+CD38low fraction, all the subsets had low BCL2 but LMPP
had high ki67 expression unlike the quiescent HSC/MPP populations (S3A and S3B Fig).
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Fig 4. ROS levels in blast cells of different AML sub-groups. DCF levels in AML blasts (gated by CD45/
SSC/CD117/CD34). Data is shown for total CD34+ blasts in CD34+AMLs (n = 70) (A) and total CD34− CD117+
blasts in CD34− AMLs (n = 23) (B) compared to the equivalent blast subset of control BMs (n = 24). AML
samples, except for CBF-AMLs (CD34+, n = 12; CD34−, n = 1), were grouped according to Flt3ITD+/NPM1
mutational status: ITD−/NPM1wt, (CD34+, n = 37; CD34−, n = 4), ITD+/NPM1wt (all CD34+, n = 6),
ITD-–/NPM1mut (CD34+, n = 7; CD34−, n = 4), ITD+/NPM1mut, (all CD34−, n = 9). Unk = represents patient
samples lacking mutational data.
doi:10.1371/journal.pone.0163291.g004
Fig 5. Combined ROS, ki67 and BCL2 staining of control and AML stem/progenitor cell subsets. Plots
show representative immunophenotypic blasts stained with DCF, ki67 and BCL2 in control BM (A)
CD34+AML BM (B) and CD34− AML BM (C). Isotype controls for each sample were performed to establish
negative gates (shown as green dotted rectangle). An expanded population with pro-survival phenotype,
ki67lowBCL2high, is observed in both AML types (B and C) and highlighted by black rectangle.
doi:10.1371/journal.pone.0163291.g005
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CD34− cells (mixedmyeloid/erythroid) in controls were as proliferative as CD34+CD38high
SPCs but had low BCL2 at levels similar to CD34+CD38low SPCs and MEP (Fig 6A and 6B).
The observedBCL2 upregulation in the GMP subset suggests that at this myeloid maturation
stage when higher ROS levels prime for proliferation/maturation, BCL2might be transiently
expressed for protection against further oxidative stress.
In CD34+ AML diagnosis samples (n = 29), a range of ki67 and BCL2 staining was observed
across CD34+CD38low, CD34+CD38high and CD34− blast subsets. Overall, however, the
blasts were less proliferative (ki67low) and, in some cases, over-expressed BCL2 compared to
Fig 6. Summarised ki67 and BCL2 expression in control, AML and MDS subsets. CD34+CD38low, CD34+CD38high and
CD34− (CD117+) blast subsets were compared for ki67-positivity (A), BCL2 expression (using BCL2-specific MFI defined by
fold increase over staining with appropriate fluorescent isotype-control mAb) and the aberrant ki67lowBCL2high phenotype (C),
which is defined using isotype control staining (see S3E Fig). Data includes 16 control BM, 29 CD34+ diagnosis AML samples
(mixed BM/PB), 6 MDS with no excess blasts (no EB) and 6 MDS-RAEB samples. The CD34− plots include data from 11
CD34− diagnosis AMLs. Median expression and interquartile range is shown on each plot. Data is shown for all AML patients
(grey squares, filled for CD34+ and open for CD34− AMLs) and genetic subgroups. F+N- denotes ITD+/NPM1wt patients (red
filled squares, all CD34+), F+N+ denotes ITD+/NPM1mut patients (red open squares, all CD34−) and F-N+ denotes ITD−/
NPM1mut (blue filled open/blue open squares for CD34+/CD34− respectively). CBF-AMLs are shown as green squares.
doi:10.1371/journal.pone.0163291.g006
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respective control subsets (Fig 6A–6C, S3C and S3D Fig). BCL2 expression was particularly
high (compared to control SPC) in the LMPP-like (CD34+CD38low) populations of several
LMPP/GMP-like AMLs as well as ki67low including all the Flt3ITD+/NPM1wt patients (S3C
and S3D Fig). CD34−AMLs (n = 11) were also significantly less proliferative and higher for
BCL2 than control CD34− CD117+ cells (Fig 5C).
AlthoughMDS-noEB (n = 6) had a normal profile, MDS-RAEBCD34+ SPCs (n = 6) were
similar to AMLs with a major aberrant ki67lowBCL2high population in both CD34+CD38low
and CD34+CD38high compartments in all samples, and for some patients (4/6) also in the
CD34− compartment (Fig 6C). We therefore identified ki67lowBCL2high phenotype as an aber-
rant blast profile in both CD34+ and CD34− AMLs and MDS-RAEB but not at the pre-leuke-
mic stage of MDS-noEB.
There was heterogeneity in the ki67lowBCL2high population frequency betweenAML sam-
ples, both for total blasts and for the immunophenotypic blast subsets (S4A and S4B Fig). The
high frequency in the Flt3ITD+/NPM1wt immature CD34+CD38low (LMPP) SPCs was consis-
tent with ki67lowBCL2high as a putative treatment-resistant ‘LSC-type’ subpopulation. The
Flt3ITD−/NPM1mutated CD34− AMLs, however, also all had a high ki67lowBCL2high blast fre-
quency (Fig 6C). Since the Flt3ITD−/NPM1mutated subgroup is associated with treatment sen-
sitivity it is likely that other functional properties attenuate any relative chemo-resistance from
the ki67lowBCL2high phenotype, at least for this more mature CD34− AML.
We hypothesised that BCL2 over-expression (with downstream effects on apoptosis, meta-
bolic regulation and cell-cycle)might be maintained in ROS-high blasts of some AMLs to
counteract further oxidative stress similar to the observedBCL2 upregulation at the GMmatu-
ration stage. We gated on blasts with 20% highest DCF fluorescence and 20% lowest DCF fluo-
rescence to allow a comparison between ROShighest and ROSlowest blasts (AML n = 40, MDS
n = 12). There was a relative enrichment of the more immature immunophenotypic SPC
(hierarchy LMPP/MPP>CMP/GMP) in the ROSlowest vs ROShighest fractions for most of the
CD34+AMLs (n = 24) (S5A Fig) but no SPC correlation with a specific ki67/BCL2profile or
overall high ROS levels. Interestingly ROSlowest/ROShighest gating of CD34+ SPCs in MDS-
noEB revealed an aberrant relative expansion of CD34+CD38low and MEP/CMP SPCs in the
ROSlowest and ROShighest fractions respectively (S5B Fig). Although some patients had lower
ki67 in ROSlowest fractions as observed for normal BM andMDS-noEB (Fig 7A–7C), the major-
ity did not have ROSlow enrichment of the LSC-like ki67lowBCL2high phenotype (S6 Fig). Simi-
lar ki67 and BCL2 levels were, however, maintained betweenROSlowest and ROShighest blasts in
a number of AML/MDS-RAEB patients. From available clinical data of early post-treatment
outcome for CD34+ AMLs, high BCL2 over-expression (>6.9-fold above isotype) in ROShighest
as well as ROSlowest fractions seemed to be most associated with initial treatment resistance
(Fig 7D) although numbers were limited. A correlation between BCL2 overexpression in
ROSlowest/ROShighest and early treatment response was not apparent in CD34− AMLs including
the Flt3ITD+/NPM1mutated patients (Fig 7E).
BCL2 inhibition experiments were performed using ABT199 in a subgroup of pre-treatment
AMLs (n = 9). High levels of ABT199 sensitivity (EC50 at or below 100nM) was observed in
both CD34+ and CD34− AMLs, irrespective of differences in intracellular ROS, BCL2 and cell-
cycle status. ABT199-induced cell death was greater than that observedusing ara-C for 5 of 6
samples (4/4 CD34+ AMLs and 1/2 CD34− AMLs) where the drug assays were performed in
parallel (S7A and S7B Fig). In the 2 samples tested, the potentially LSC-enriched, immature
CD34+CD38low blast fractions showed equivalent or greater ABT199 sensitivity than more
mature CD34+CD38high blasts (S7C Fig) and had a similar profile of differential sensitivity to
ABT199 compared to ara-C (S7D Fig).
Functional Profiles of Normal and AML Stem/Progenitor Cells
PLOS ONE | DOI:10.1371/journal.pone.0163291 September 26, 2016 12 / 19
Fig 7. ROS-separated ki67 and BCL2 expression in AML stem/progenitor cells. AML progenitors stained with mAb for
surface markers, DCF, ki67 and BCL2 were separated into ROSlowest and ROShighest cells based on the 20% dimmest and
20% brightest DCF staining populations respectively. Charts show ki67 and BCL2 expression respectively in ROSlowest and
ROShighest subsets in (A-B) CD34+ AMLs, (C-D) in CD34− AMLs and (E-F) in CD34+ cells in MDS patients with no excess
blasts (no EB) and MDS patients with excess blasts (RAEB-1/RAEB-2). Profiles from 5 representative control/normal BMs
are shown for CD34+ and CD34−CD117+ cells in the respective charts (grey triangles). AML patients were subdivided into
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Discussion
This study provides a phenotypic profile for normal and leukemic SPC-subsets of functional
cell properties that may, by dysregulation downstream of genetic abnormalities, promote sur-
vival and propagation in AML. Our results show decoupling of the relationship between nor-
mal myeloid maturation and cellular ROS/ BCL-2/ cell-cycle profiles in AML and MDS-RAEB
with certain leukemic blast subpopulations displaying a chimeric functional phenotype of both
‘stem-cell-like’ and ‘GM-like’ properties. Normal human CD34+ and CD34−CD117+ SPC sub-
sets exhibit distinct patterns of ROS, cell-cycle activity with BCL2 expression upregulation at
the GM stage. These ROS/ cell-cycle patterns are lost in AML and MDS-RAEBwith an aber-
rant ki67lowBCL2high phenotype observed in both CD34+ and CD34− blast subpopulations at
disease presentation.
By combining immunophenotypic characterisation of normal human SPC subsets with a
ROS assay we show that although the DCF-low/ROS-low state has been associated with greater
quiescence and the DCF-high/ROS-high state with proliferation and differentiation in primi-
tive hematopoietic cells [20], the more mature (CD34+CD38high) progenitors actually contain a
combination of ROS-low and ROS-high cells with MEP consistently ROS-low, and GMP being
ROS-high while CMP are a mixture of ROS-high/low cells. Colony assay data support a model
whereby ROS-high CMP are pre-committed to becomeGMP while ROS-low CMP are either
less committed and/or pre-committed to MEP. This ROS-based separation of human CMP is
consistent with ROS being a driver of myeloid differentiation [6,7,35]. Extending our analysis
by evaluation of the combined ROS/cell-cycle/BCL2 profile showed that all subsets (GMP/
CMP/MEP) of CD34+CD38high cells had high levels of cell-cycle activity despite variation in
ROS levels but BCL2 upregulation correlated with increasing ROS levels and was thus mye-
loid-specific. BCL2 protein upregulation may be a survival cue to counteract oxidative stress-
induced apoptosis in GMPs when higher ROS levels are required to prime for proliferation/
maturation. It could also be speculated, however, to predispose GMP to accumulatingmore
DNA damage [36] and explain the relative expansion of GMP rather than CMP as observed in
most MDS-RAEB and AML patients [28,37].
All normal CD34+CD38low SPCs were BCL2low and, as expected,HSC and MPP were ROS-
low ki67low (quiescent) but interestingly the infrequent LMPP population appeared less ‘stem-
cell-like’ with higher ROS and greater cell-cycle activity. The immunophenotypically immature
SPCs of AML and MDS-RAEB samples had the lowest ROS levels but the overall ROS profile
was less heterogeneous compared to normal; the CD34+CD38high (GMP-like in particular) and
CD34−AML ‘mature’ blasts were both lower in ROS than the immunophenotypic equivalent
control SPCs. This shift towards immature SPC ROS levels may contribute to the differentia-
tion block in AML, consistent with data showing that agents increasing ROS can induce matu-
ration of AML blasts [38,39]. The ROS-low pattern was observed, often more distinctly, in
AML cells in PB and may represent an adaptation of AML sub-clones in BM that traffic to the
PB [40] akin to that of HSPC preserving their hypoxic status while circulating in the normoxic
blood environment [41].
While intracellular ROS levels varied in our cohort (~12-fold range), this was lower than the
variation reported for extracellular ROS produced by AML blasts (4-log range) using different
Flt3ITD+/NPM1wt (simplified to F+/N-), Flt3ITD−/NPM1mut (F-/N+), Flt3ITD+/NPM1mut (F+N+), CBF-AMLs, t(9;11)-AMLs
and other cases. AML patients with poor early response (refractory/ early-relapse/ delayed remission) indicated by red
squares. Patients achieving stable remission after one course of treatment are shown as black squares. Patients for whom
early outcome data was unavailable are shown as grey squares. Thresholds for high BCL2 expression are shown as dashed
lines on each BCL2 chart. The threshold was set at >mean+2SD of normal CD34+ (>6.9) or CD34− blasts (>3.3).
doi:10.1371/journal.pone.0163291.g007
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methods of ROS detection [18]. It is plausible that extracellular ROS production is also high in
our patients while intracellular ROS is kept under control by an enhanced anti-oxidant
response [42,43], which may be targetable for inhibition [44–45]. Our data partially support
the link between Flt3ITD+ mutation and higher ROS levels [15] but also show that ROS levels
were lower in mostNPM1-mutated/ Flt3ITD+ cases (all CD34− AML in our cohort). Though
patient numbers are low, this could suggest that theNPM1-mutated phenotype mitigates the
effect of Flt3ITD+ on intracellular ROS levels, resulting in a lower risk of DNA damage and
progression as suggested by clinical data [46]. Higher ROS levels were also observed in some
CBF-AMLs which is interesting as ROS signalling is crucial for maintaining AML1-ETO fusion
protein-induced aberrant progenitor cells in a drosophila model [31]. The elevated ROS of
CBF-AMLs may be related to both granulocyticmaturation and enhanced sensitivity to che-
motherapy by the mechanism of ROS-induced apoptosis.
We also detected higher ROS than controls in SPCs of MDS-noEB, most marked in the ery-
throid precursor-enriched subset (CD117+CD34−CD45RA−). This may be linked with the
reported higher apoptosis and cytopenias observed in MDS patients [37] from increased oxida-
tive stress particularly of the erythroid lineage. Reduced ki67 expression, high BCL2 expression
and most significantly an expanded ki67lowBCL2high phenotype were observed in AML and
MDS-RAEB but not MDS-noEB.While the ki67lowBCL2high aberrant phenotype was highly
expanded in Flt3ITD+ cases including in the LSC-enriched LMMP-like subpopulation [28], it
was also present in other AML subtypes. The in vivo LSC frequency of identified ki67lo-
wBCL2highcells could not be investigated by xenografting experiments due non-viability follow-
ing intracellular staining but ki67 and BCL2 expression, either as single parameters or when
combined as ki67lowBCL2high, did not correlate with early outcome to standard treatment in
our small patient group. This is not unexpected as chemo-resistance is also dependent on the
balance between activities of different pro-/anti-apoptotic BCL2 family proteins [47–49] as
well as drug efflux activity [50]. Further sub-analysis of ROShighest and ROSlowest cells within
the blast population of each patient showed that, although aberrant BCL2 overexpression has
been reported as an adaptation of LSC-enrichedROSlowest AML cells [2], ROShighest cells were
also BCL2high for some CD34+ AMLs (8/24) and CD34− AMLs (7/9). Intriguingly, aberrant
overexpression of BCL2 in ROShighest as well as ROSlowest blasts was the profile most associated
with early chemotherapy resistance from limited available data in the 24 CD34+ AMLs with
outcome data. However, sensitivity to BCL2 inhibition in vitro using ABT199 in a small num-
ber of tested patients was high across both CD34+ and CD34- AML blast types with different
ROS, ki67 and BCL2 levels. Furthermore AML blasts including potentially LSC-enriched
fractions, showed greater sensitivity to ABT199 than ara-C. Thus BCL2 dependencewas
shared by phenotypically different AML blasts. This in vitro data is supportive of greater clini-
cal efficacy of BCL2-inhibition therapy across different AML subtypes compared to standard
chemotherapy.
It may also be postulated from our results that BCL2 over-expression (with downstream
effects on apoptosis, metabolic regulation and cell-cycle) is an adapted ‘GM-like’ property (to
intrinsic or extrinsic dysregulation) that in some AMLs modulates the apoptotic threshold to
additional oxidative stress as well as metabolic adjustments. This could contribute to relative
chemo-resistance by protecting leukemic blasts with higher ROS from apoptosis triggered by
chemotherapy-induced oxidative damage.
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